安罗替尼治疗晚期非小细胞肺癌的临床效果(1)
[摘要] 目的 观察安罗替尼治疗晚期非小细胞肺癌(NSCLC)的效果及不良反应。 方法 选取2018年5～10月徐州市中心医院肿瘤内科及呼吸科收治的晚期NSCLC患者(既往接受过二线或以上治疗)共40例，采用随机数字表法分为观察组和对照组，每组20例。观察组口服安罗替尼12 mg/d，连服2周，停药1周，21 d为1个周期;对照组采用最佳支持治疗。观察两组的客观缓解率、疾病控制率、无进展生存期、总生存期及不良反应。 结果 两组客观缓解率比较，差异无统计学意义(P > 0.05);观察组疾病控制率明显高于对照组(P < 0.05);观察组无进展生存及总生存均显著高于对照组(P < 0.05);观察组多为1～2级不良反应，3～4级不良反应主要见于手足综合征、口腔黏膜炎、纳差及疲劳。 结论 安罗替尼治疗晚期NSCLC有一定效果，不良反应可耐受。
[关键词] 安罗替尼;肺肿瘤;晚期肺癌;靶向治疗
[中图分类号] R734.2 [文献标识码] A [文章编號] 1673-7210(2019)11(b)-0095-04
Clinical efficacy of Anlotinib in the treatment of advanced non-small cell lung cancer
DAI Xiumei1 ZHANG Youwei1 HAN Liang1 LIU Yanhua1 LI Ruoran2
1.Department of Oncology， Xuzhou Central Hospital， Jiangsu Province， Xuzhou 221009， China; 2.Department of Respiration， Xuzhou Central Hospital， Jiangsu Province， Xuzhou 221009， China
[Abstract] Objective To observe the efficacy and adverse effect of Anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 40 patients with advanced NSCLC (after second-line or further treatment) admitted to the Department of Oncology and Respiration of Xuzhou Central Hospital from May to October 2018 were admitted. They were randomly divided into observation group and control group according to the random number table method， with 20 cases in each group. The observation group was treated with Anlotinib (12 mg/d， 2 weeks on-treatment followed by 1 week off-treatment in a 21-day cycle)， while the control group was treated with best supportive care. Objective response rate， disease control rate， progression free survival， overall survival and adverse effect were observed. Results There was no statistically significant difference in objective response rate between two groups (P > 0.05). The disease control rate in the observation group was significantly higher than that in the control group (P < 0.05). The progression free survival and overall survival in the observation group were significantly higher than those in the control group (P < 0.05)， grade 1-2 adverse effects were common in the observation group， grade 3-4 adverse effects were mainly associated with hand-foot syndrome， oral mucositis， poor appetite and fatigue. Conclusion Anlotinib is effective in the treatment of advanced NSCLC， and the adverse effects were tolerable.
[Key words] Anlotinib; Lung neoplasms; Advanced lung cancer; Targeted therapy, http://www.100md.com(戴秀梅 张有为 韩亮)
[关键词] 安罗替尼;肺肿瘤;晚期肺癌;靶向治疗
[中图分类号] R734.2 [文献标识码] A [文章编號] 1673-7210(2019)11(b)-0095-04
Clinical efficacy of Anlotinib in the treatment of advanced non-small cell lung cancer
DAI Xiumei1 ZHANG Youwei1 HAN Liang1 LIU Yanhua1 LI Ruoran2
1.Department of Oncology， Xuzhou Central Hospital， Jiangsu Province， Xuzhou 221009， China; 2.Department of Respiration， Xuzhou Central Hospital， Jiangsu Province， Xuzhou 221009， China
[Abstract] Objective To observe the efficacy and adverse effect of Anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 40 patients with advanced NSCLC (after second-line or further treatment) admitted to the Department of Oncology and Respiration of Xuzhou Central Hospital from May to October 2018 were admitted. They were randomly divided into observation group and control group according to the random number table method， with 20 cases in each group. The observation group was treated with Anlotinib (12 mg/d， 2 weeks on-treatment followed by 1 week off-treatment in a 21-day cycle)， while the control group was treated with best supportive care. Objective response rate， disease control rate， progression free survival， overall survival and adverse effect were observed. Results There was no statistically significant difference in objective response rate between two groups (P > 0.05). The disease control rate in the observation group was significantly higher than that in the control group (P < 0.05). The progression free survival and overall survival in the observation group were significantly higher than those in the control group (P < 0.05)， grade 1-2 adverse effects were common in the observation group， grade 3-4 adverse effects were mainly associated with hand-foot syndrome， oral mucositis， poor appetite and fatigue. Conclusion Anlotinib is effective in the treatment of advanced NSCLC， and the adverse effects were tolerable.
[Key words] Anlotinib; Lung neoplasms; Advanced lung cancer; Targeted therapy, http://www.100md.com(戴秀梅 张有为 韩亮)